<p style="text-align: justify;"The cheap drug aspirin does not improve the condition of patients hospitalized with Kovid-19. This disclosure has come from a research conducted in Britain. Researchers at Oxford University hoped that the blood-thinning drug could help hospitalized Kovid-19 patients. Significantly, the risk of blood clots is very high in Kovid-19 patients.
aspirin did not help in the treatment of covid-19
<p style="text-align: justify;"Researchers wanted to know whether aspirin could prove helpful in reducing the risk of blood clots in Kovid-19 victims. Research on aspirin started on Kovid-19 patients in November last year. Researchers found that the drug could not help prevent death. Under the trial called 'Recovery', various possible drugs are being tested for people hospitalized due to corona virus. About 15 thousand patients hospitalized with corona virus were included in the trial. Half of the patients were given a daily dose of 150 mg aspirin, while half were treated as usual.
28 days later, the mortality rate in both groups was 17 percent
Researchers found in research, "There was no evidence that aspirin treatment reduced mortality." And "There was no clear difference in the number of people who died." After 28 days of hospital treatment, the mortality rate in both the groups was 17 percent. Although the use of aspirin slightly increased the patient’s chance of survival, this is not enough to justify its widespread use for patients hospitalized with COVID-19. Professor Martin Lindray, a member of the research team, described the research results as disappointing.
he said, "There is a strong indication that blood clotting may be responsible for lung function impairment and death in patients with severe COVID-19. Aspirin is a widely used and inexpensive drug to reduce the risk of blood clots among other diseases. Therefore, the results are disappointing that those patients did not get any significant benefit from its use. The results of the research on aspirin have not been published in any journal, but have been released on the pre-print server medRxiv.